Nevro Corp. (NVRO) Raised to “Hold” at BidaskClub

BidaskClub upgraded shares of Nevro Corp. (NYSE:NVRO) from a sell rating to a hold rating in a report published on Saturday.

A number of other analysts have also weighed in on the stock. BMO Capital Markets restated a buy rating and set a $106.00 price objective on shares of Nevro Corp. in a research note on Friday, September 1st. Zacks Investment Research lowered shares of Nevro Corp. from a buy rating to a hold rating in a research note on Friday, August 11th. Northland Securities restated a buy rating and set a $96.00 price objective on shares of Nevro Corp. in a research note on Tuesday, August 8th. Morgan Stanley raised their price objective on shares of Nevro Corp. from $87.00 to $95.00 and gave the company an overweight rating in a research note on Tuesday, August 8th. Finally, Canaccord Genuity restated a buy rating and set a $120.00 price objective on shares of Nevro Corp. in a research note on Wednesday, July 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $101.25.

Nevro Corp. (NVRO) opened at 92.24 on Friday. Nevro Corp. has a 12-month low of $65.82 and a 12-month high of $102.26. The stock’s market capitalization is $2.72 billion. The company’s 50-day moving average is $88.22 and its 200 day moving average is $83.73.

Nevro Corp. (NYSE:NVRO) last released its quarterly earnings data on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.11). The firm had revenue of $78.02 million for the quarter, compared to the consensus estimate of $77.75 million. Nevro Corp. had a negative net margin of 14.33% and a negative return on equity of 16.25%. The firm’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.31) earnings per share. On average, equities research analysts expect that Nevro Corp. will post ($1.16) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/10/10/nevro-corp-nvro-raised-to-hold-at-bidaskclub.html.

In other news, CFO Andrew H. Galligan sold 7,000 shares of Nevro Corp. stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $82.31, for a total value of $576,170.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael F. Demane sold 5,000 shares of Nevro Corp. stock in a transaction that occurred on Wednesday, September 27th. The stock was sold at an average price of $91.50, for a total transaction of $457,500.00. The disclosure for this sale can be found here. Insiders sold 285,907 shares of company stock valued at $24,202,565 over the last quarter. Company insiders own 12.10% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Dorsey & Whitney Trust CO LLC grew its stake in shares of Nevro Corp. by 0.3% in the second quarter. Dorsey & Whitney Trust CO LLC now owns 27,871 shares of the medical equipment provider’s stock worth $2,074,000 after acquiring an additional 85 shares during the period. Prudential Financial Inc. grew its stake in shares of Nevro Corp. by 13.8% in the second quarter. Prudential Financial Inc. now owns 2,878 shares of the medical equipment provider’s stock worth $214,000 after acquiring an additional 350 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of Nevro Corp. by 17.3% in the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after acquiring an additional 358 shares during the period. Legal & General Group Plc grew its stake in shares of Nevro Corp. by 5.4% in the first quarter. Legal & General Group Plc now owns 8,137 shares of the medical equipment provider’s stock worth $760,000 after acquiring an additional 418 shares d

A number of other analysts have also weighed in on the stock. BMO Capital Markets restated a buy rating and set a $106.00 price objective on shares of Nevro Corp. in a research note on Friday, September 1st. Zacks Investment Research lowered shares of Nevro Corp. from a buy rating to a hold rating in a research note on Friday, August 11th. Northland Securities restated a buy rating and set a $96.00 price objective on shares of Nevro Corp. in a research note on Tuesday, August 8th. Morgan Stanley raised their price objective on shares of Nevro Corp. from $87.00 to $95.00 and gave the company an overweight rating in a research note on Tuesday, August 8th. Finally, Canaccord Genuity restated a buy rating and set a $120.00 price objective on shares of Nevro Corp. in a research note on Wednesday, July 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $101.25.

Nevro Corp. (NVRO) opened at 92.24 on Friday. Nevro Corp. has a 12-month low of $65.82 and a 12-month high of $102.26. The stock’s market capitalization is $2.72 billion. The company’s 50-day moving average is $88.22 and its 200 day moving average is $83.73.

Nevro Corp. (NYSE:NVRO) last released its quarterly earnings data on Monday, August 7th. The medical equipment provider reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.11). The firm had revenue of $78.02 million for the quarter, compared to the consensus estimate of $77.75 million. Nevro Corp. had a negative net margin of 14.33% and a negative return on equity of 16.25%. The firm’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.31) earnings per share. On average, equities research analysts expect that Nevro Corp. will post ($1.16) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/10/10/nevro-corp-nvro-raised-to-hold-at-bidaskclub.html.

In other news, CFO Andrew H. Galligan sold 7,000 shares of Nevro Corp. stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $82.31, for a total value of $576,170.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael F. Demane sold 5,000 shares of Nevro Corp. stock in a transaction that occurred on Wednesday, September 27th. The stock was sold at an average price of $91.50, for a total transaction of $457,500.00. The disclosure for this sale can be found here. Insiders sold 285,907 shares of company stock valued at $24,202,565 over the last quarter. Company insiders own 12.10% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Dorsey & Whitney Trust CO LLC grew its stake in shares of Nevro Corp. by 0.3% in the second quarter. Dorsey & Whitney Trust CO LLC now owns 27,871 shares of the medical equipment provider’s stock worth $2,074,000 after acquiring an additional 85 shares during the period. Prudential Financial Inc. grew its stake in shares of Nevro Corp. by 13.8% in the second quarter. Prudential Financial Inc. now owns 2,878 shares of the medical equipment provider’s stock worth $214,000 after acquiring an additional 350 shares during the period. Ameritas Investment Partners Inc. grew its stake in shares of Nevro Corp. by 17.3% in the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after acquiring an additional 358 shares during the period. Legal & General Group Plc grew its stake in shares of Nevro Corp. by 5.4% in the first quarter. Legal & General Group Plc now owns 8,137 shares of the medical equipment provider’s stock worth $760,000 after acquiring an additional 418 shares during the period. Finally, Denver Investment Advisors LLC grew its stake in shares of Nevro Corp. by 4.6% in the second quarter. Denver Investment Advisors LLC now owns 10,162 shares of the medical equipment provider’s stock worth $756,000 after acquiring an additional 445 shares during the period.

About Nevro Corp.

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Analyst Recommendations for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply